ELYM - Eliem Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-28.78M

Cash

109.4M

Avg Qtr Burn

-10.44M

Short % of Float

0.23%

Insider Ownership

26.65%

Institutional Own.

68.47%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ETX-123 (Kv7.2/3 channel opener) Details Epilepsy, Pain, Seizures	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-810 Details Chronic pain, Pain, Sciatica	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-810 Details Chronic pain, Sciatica , Pain, Diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-155 Details Epilepsy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ETX-155 Details Major depressive disorder, Perimenopausal Depression	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.